What question did this study set out to answer?

This review aims to evaluate the survival outcomes and pathological responses following neoadjuvant treatment in esophagogastric cancer.

August 13, 2026DiagnosticsOpen Access

Survival and Pathologic Response After Neoadjuvant Treatment in Esophagogastric Cancer

View Full Paper

Ask AI

Bookmark

This review aims to evaluate the survival outcomes and pathological responses following neoadjuvant treatment in esophagogastric cancer.
Systematic review adhering to PRISMA 2020 guidelines.
Included studies published from January 2020 to September 2025 on adults with resectable EGC treated with neoadjuvant CT or CRT.
A total of sixty studies were analyzed, comprising 18 randomized controlled trials and 42 cohort analyses.
pCR rates ranged from 8% to 49%; CRT had a mean pCR of 33% and major TRG response of 63%, compared to CT alone with pCR of 22% and TRG of 48%.
Immunotherapy-enhanced protocols (IO-CRT and IO-CT) reported mean pCR rates of 48-50%.
Patients with complete or major regression achieved superior OS and DFS, validating pathological response as a prognostic marker.

No takes yet. Share an insight, caveat, or question.

Systematic review shows neoadjuvant treatment improves survival in esophagogastric cancer, indicating need for standardized assessments.

Marica et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark